

PTO/SB/08a (03-09)  
Approved for use through 04/30/2009. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	1	of	5
-------	---	----	---

Application Number	10/581,761
Filing Date	April 10, 2008

First Named Inventor	Mats Hellstrom et al.
----------------------	-----------------------

Art Unit

Examiner Name

Attorney Docket Number	102959-202
------------------------	------------

## U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	6.	WO 2003/079982 A2	10-02-2003	Li, Jing et al.		
	7.	WO 2003/072827 A1	09-04-2003	Hirsch, Raphael et al.		
	8.	WO 2003/046578 A2	06-05-2003	Chibout, Salah-Dine et al		
	9.	WO 2003/026403 A2	04-03-2003	Wisotzkey, Robert G et al		
	10.	WO 2002/094780 A2	11-28-2002	Yue, Henry et al.		
	11.	WO 2002/079492 A2	10-10-2002	Murray, Richard et al.		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Sheet 3 of 5	<b>Complete if Known</b>	
	Application Number	10/581,761
	Filing Date	April 10, 2008
	First Named Inventor	Mats Hellström et al.
	Art Unit	
	Examiner Name	
	Attorney Docket No.	102959-202

**NON PATENT LITERATURE DOCUMENTS**

EXAMINER INITIAL*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	15.	BOHLING, FRANK ET AL., "Cathepsins K, L, B, X and W are differentially expressed in normal and chronically inflamed gastric mucosa", BIOLOGICAL CHEMISTRY, Vol. 385, Pages 439-445 (2004).	
	16.	TIGYI, GABOR JOSEPH ET AL., "Multiple phenotypic abnormalities in lipid phosphate phosphatase-1 transgenic mice without alteration in lysophosphatidate level and signaling", FASEB JOURNAL, Vol. 17, No. 405, Abstract No. 123.7 (2003).	
	17.	SMYTH, SUSAN S. ET AL., "Lipid phosphate phosphatases regulate lysophosphatidic acid production and signaling in platelets. Studies using chemical inhibitors of lipid phosphate phosphatase activity", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 44, Pages 43214-43223 (2003).	
	18.	TANYI J. L. ET AL., "Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer", CLINICAL CANCER RESEARCH, Vol. 9, No. 101, Pages 3534-3545 (2003).	
	19.	SONG, ZHI-QIANG ET AL., "Analysis and screening of differentially expression genes of dermal papillae cells with aggregative behavior", ZHONGHUA PIFUKE ZAZHI, Vol. 36, No. 9, Pages 513-515 (2003).	
	20.	SHIN, JORDAN T. ET AL., "From zebrafish to humans: Modular medical models", ANNU. REV. GENOMICS AND HUMAN GENETICS, Vol. 3, Pages 311-340 (2002).	
	21.	CLARK, MATTHEW D. ET AL., "An oligonucleotide fingerprint normalized and expressed sequence tag characterized zebrafish library", GENOME RESEARCH, Vol. 11, No. 9, Pages 1564-1602 (September 2001).	
	22.	NASEVICIUS, AIDAS ET AL., "Effective targeted gene 'knockdown' in zebrafish", NATURE GENETICS, Vol. 26 (October 2000).	
	23.	DEUSSING, JAN ET AL., "Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization", BIOCHIMICA ET BIOPHYSICA ACTA, Vol. 1491, Pages 93-106 (2000).	
	24.	BOUKHELIFA M. ET AL., "Palladin, a novel cytoskeleton associated protein involved in neural maturation", SOCIETY FOR NEUROSCIENCE ABSTRACTS, Vol. 26, No. 1-2, Abstract No. 314.7 (2000).	
Examiner		Date	
Signature:		Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through if not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Sheet 4 of 5	<i>Complete if Known</i>	
	Application Number	10/581,761
	Filing Date	April 10, 2008
	First Named Inventor	Mats Hellström et al.
	Art Unit	
	Examiner Name	
	Attorney Docket No.	102959-202

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	25.	ZHU, ZHENPING ET AL., "Inhibition of tumor growth and metastasis by targeting tumor-associate angiogenesis with antagonists to the receptors of vascular endothelial growth factor", INVESTIGATIONAL NEW DRUGS, Vol. 17, Pages 195-212 (1999).	
	26.	KAI, MASAHIRO ET AL., "Cloning and characterization of two human isozymes of Mg <sup>2+</sup> independent phosphatidic acid phosphatases", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 38, Pages 24572-24578 (1997).	
	27.	KAI, MASAHIRO ET AL., "Identification and CDNA cloning of 35-KDA phosphatidic acid phosphatase (type2) bound to plasma membranes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 271, No. 31, Pages 18931-18938 (1996).	
	28.	INNIS MICHAEL A. ET AL., "Optimization of PCRs - PCR Protocols, A Guide to Methods and Applications", ACADEMIC PRESS, INC. (1990).	
	29.	Database EPO Proteins (online) Accession No. CQ896404, HINZMANN, B. ET AL., "Human nucleic acid sequences obtained from prostatic carcinomas", 5 November 2004 (2004-11-05).	
	30.	Database EMBL (online) Accession No. CG597335, ZAMBROWICZ, B. P. ET AL., "Wnkl kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention", 8 October 2003 (2003-10-08).	
	31.	Database EMBL (online) Accession No. CD541309, PIAO, Y. ET AL., "Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method", 12 June 2003 (2003-06-12).	
	32.	Database EMBL (online) Accession No. AK088577, ADACHI, J. ET AL., "The transcriptional landscape of the mammalian genome", 19 December 2002 (2002-12-19).	
	33.	Database EMBL (online) Accession No. AX140435, WOLF, E. ET AL., "Use of polypeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in identifying pharmacologically active substances", 31 May 2001 (2001-05-31).	

Examiner

Date

Signature:

Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through if not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Sheet 5 of 5	<i>Complete if Known</i>	
	Application Number	10/581,761
	Filing Date	April 10, 2008
	First Named Inventor	Mats Hellström et al.
	Art Unit	
	Examiner Name	
	Attorney Docket No.	102959-202

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIAL*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	34.	Database EMBL (online) Accession No. AF136273, DEUSSING, J ET AL., "Murine and human cathepsin Z: cDNA-cloning, characterization of the genes and chromosomal localization", 26 November 1999 (1999-11-26).	
	35.	Database EMBL (online) Accession No. AB000888, KAI, M. ET AL., "Cloning and characterization of two human isozymes of Mg <sup>2+</sup> -independent phosphatidic acid phosphatase", 7 October 1997 (1997-10-07).	
Examiner	Date		
Signature:	Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through if not considered. Include copy of this form with next communication to applicant.